MTOR Inhibitors in Older Adults

Launched by UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER · Dec 8, 2024

Keywords

ClinConnect Summary

This clinical trial, titled "MTOR Inhibitors in Older Adults," is exploring the use of certain medications called mTOR inhibitors, which may help slow down the aging process and prevent age-related diseases. The main goal is to gather important information about how these drugs work in older adults, as there is currently not enough data on their effects in this age group. This study aims to lay the groundwork for future research on mTOR inhibitors and their potential benefits for aging-related health issues.

To participate in this trial, individuals need to be 65 years or older and living independently in the community. They should also be able to understand and follow the study procedures. However, certain health conditions, such as severe kidney or liver problems, uncontrolled high blood pressure, or recent serious health events like heart issues, may exclude someone from participating. If eligible, participants can expect to engage in a study that will help improve our understanding of how to support healthy aging in older adults. It’s also important to note that this trial is not yet recruiting participants, so there will be more information available in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Community-dwelling adults
• • 2. Patients should be 65 Years and older
• • 3. Patients is able to understand and follow trial procedures
• Exclusion Criteria:
• • 1. Creatinine clearance \<30 mL/min;
• • 2. History of chronic liver disease;
• • 3. Uncontrolled Hypertension (i.e., systolic blood pressure \>160 mm Hg);
• • 4. Hemorrhagic central nervous system (CNS) event within 1 year from screening visit;
• • 5. Thrombotic event (DVT,PE) within 1 year from screening visit if not on anticoagulation;
• • 6. Planned major surgical procedures;
• • 7. Cardiovascular diseases ( i.e., admission for heart failure or myocardial infarction within 12 months);
• • 8. Taking medication that increase or decrease sirolimus blood concentrations;
• • 9. Other investigational therapy received within 1 month prior to screening visit;
• • 10. History of dementia; 11 Dependence in any Katz Basic Activities of Daily Living.